MAR vs MRNA
Head-to-Head Stock Analysis & Investment Rating
Last Updated: Sep 17, 2026
MAR
MRNA
Investment Advisor Scores
MRNA
AI Analyst Insights
Detailed Metrics Comparison
| Metric | MAR | MRNA | Winner |
|---|---|---|---|
|
Valuation
Lower P/E and PEG ratios suggest a stock may be undervalued relative to earnings and growth. Value investors prefer lower multiples. |
|||
| Forward P/E | 25.4453 | 23.0415 | MRNA |
| PEG Ratio | 1.6868 | 0 | Tie |
|
Growth
Higher revenue and earnings growth rates indicate a company is expanding faster. Strong growth often justifies premium valuations. |
|||
| Revenue Growth | 11.1% | 2.1% | MAR |
| Earnings Growth | 4.3% | -85.1% | MAR |
|
Quality & Profitability
Higher Tradestie Score and profit margins reveal how efficiently a company operates. Strong profitability indicates competitive advantages. |
|||
| Tradestie Score | 62.1/100 | 34.1/100 | MAR |
| Profit Margin | 35.0% | -141.4% | MAR |
|
Risk Profile
Lower Beta and Implied Volatility values indicate reduced market risk. Conservative investors favor stocks with less price volatility. |
|||
| Beta | 1.00 | 1.00 | Tie |
|
Sentiment
AI Recommendation reflects overall analyst and proprietary sentiment. Stronger recommendations signal higher conviction. |
|||
| AI Recommendation | STRONG BUY | SELL | MAR |
Relative Price Performance (Last 90 Days)
Current Technical Phase
MAR
NeutralMixed signals - no dominant trend phase, RSI 56
MRNA
MarkupPrice above SMA50, rising 50-day trend (49.6% over 20 days), RSI 64
Fundamentals Snapshot
| Metric | MAR | MRNA |
|---|---|---|
| Market Cap | — | — |
| Forward P/E | 27.1 | -41.0 |
| Trailing P/E | 37.4 | — |
| Revenue (TTM) | — | — |
| Revenue Growth | 0.1% | 0.0% |
| Gross Margin | 0.8% | -0.7% |
| Operating Margin | 0.7% | -5.6% |
| EPS | 9.66 | -7.36 |
| Dividend Yield | 0.01% | — |